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A Critical View of Helminthic Therapy: Is it a viable form of treatment for immune disorders 
under the category of inflammatory bowel disease? 
Abstract 
In the developed world, Crohn’s disease and colitis affects the lives of many individuals. 
Recently, a new form of treatment for these autoimmune diseases has gained recognition. This 
treatment uses helminths (​Trichuris trichiura ​ and ​Trichuris suis​ ) as an immunomodulant to a 
human immune system. Various studies (Summers ​et. al​ ., 2004; Dige ​et. al​ ., 2016; Lopes et. al., 
2016) have shown the safety and viability of this form of treatment, but many believe this area of 
research leaves much to be desired. Through this paper, the topic of helminthic therapy and its 
viability as a form of treatment for autoimmune diseases under the category of inflammatory 
bowel disease (IBD) will be discussed. A conclusion will be reached by reviewing these three 
key studies: ​Helminth Regulation of Immunity: A Three-pronged Approach to Treat Colitis ​ by 
Lopes ​et. al​ ., ​Trichuris suis therapy in Crohn’s disease ​ by Summers ​et. al​ ., and ​Mucosal and 
systemic immune modulation by Trichuris trichiura in a self-infected individual​  by Dige ​et. al​ . 
 
Part 1: Helminths 
 
Understanding the following research includes a knowledge of certain key terms. The 
terms “helminth” or “helminthic therapy” are casting an incredibly broad net. Helminth is a 
vague term meaning “worm”. Pre-fixes are used to distinguish the different types of helminths; 
the main two being platy-helminth (flatworms) and nemat-helminth (roundworms) (Weinstock, 
2012). Both species of helminths commonly used in helminthic therapy are nemat-helminth, and 
specifically whipworms. ​Trichuris trichiura​  (​T.trichiura​ ) is the human whipworm, and ​Trichuris 
suis​  (​T.suis​ ) is the pig whipworm (Cross, 1996). Focusing on the evolutionary paths and 
interactions with a human host for these two species of helminths will shed light on the viability 
of helminthic therapy for inflammatory bowel disease (IBD). 
Parasites and parasitic roundworms have history that dates back to the beginning of man. 
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Written record of parasitic infection is seen in Egyptian medicine, and recently a new section of 
science has developed called paleoparasitology (Cox, 2002). The discovery of helminth eggs in 
fossilized feces spurred the development of paleoparasitology, and has furthered understanding 
of the history of parasitic helminths. Through this look at the history of human-parasite 
interaction, various theories have arisen. Many believe we have “heirloom” parasites, which 
were inherited from our primate ancestors (Cox, 2002). Along with these passed down parasites, 
humans have picked up “souvenir” parasites while we spread across the globe. With the rise in 
global trading throughout human history, many parasites have been passed from one population 
of humans to another (Hawash ​et. al​ ., 2016). This trading resulted in a wide spread of human 
parasites (about 300 species). Although humans are the hosts for these many parasites, with the 
rise of technology, many parts of the world rarely experience infection. The hygiene hypothesis 
is a theory that looks at the effect of this loss of parasitism on humans, and is part of the basis for 
researching helminthic therapy (Robinson and Bradley, 2010).  
Its complex life cycle consists of six distinct stages (CDC, 2013). Beginning with 
unembryonated eggs being released through the feces (usually human), they then develop into a 
two cell organism  and advance to a cleavage stage outside of their human host (CDC, 2013). 
Following these stages, the eggs become embryonated, and are able to start infecting their human 
host (CDC, 2013). The eggs are then ingested (through contact with infected soil), and once 
inside the host, the eggs will hatch in the small intestine and release larvae (CDC,2013). Once 
mature, the adult whipworm will attach itself in the ascending colon and cecum, and the females 
will start to produce eggs (CDC, 2013). Adults are around four centimeters in length, and can 
shed anywhere from 3,000 to 20,000 eggs per day, thus starting the cycle again (CDC, 2013). 
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 Figure 1: Life cycle of ​T. trichiura. ​ (CDC, 2013) 
In order to complete its life cycle, ​T. trichiura​  must advert the host's immune system. All 
helminths secrete large amounts of antigenic material, which many believe overloads the human 
immune system and renders it useless (Wakelin, 1996). Since ​T. trichiura​  (like many other 
helminths) is large and motile, it is physically able to withstand attacks from its host (from both 
the immune system and the high acidity of the stomach). Another explanation as to why ​T. 
trichiura​  is able to survive the human immune system is through the secretion of lymphocyte 
suppressor factors, which will reduce immune responsiveness (Wakelin, 1996). It is this 
explanation that is a major part of the basis for research of helminthic therapy, and why an 
infection of helminths could combat the symptoms of IBD.  
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The helminth ​T. suis​  is also playing a part in helminthic therapy research. The life cycle 
of ​T. suis​  is almost identical to that of ​T. trichiura​ , except that it has co-evolved with the primary 
host as a pig (Pittman ​et. al​ ., 2010). Because of this coevolution with pigs, ​T. suis ​ is not as adept 
at avoiding a human immune attack as ​T. trichiura​ . However, like many other helminths,​ T. suis 
still secretes certain suppressants that lower immune responsiveness even in humans (Summers 
et. al​ ., 2004). Since ​T. suis​  shares these immunomodulatory aspects with ​T. trichiura​ , but usually 
are unable to withstand a human environment for long, they make an optimal candidate for 
helminthic therapy research (Summers ​et. al​ ., 2003). 
Part 2: The Immune System 
Another important part of this research is the role of the human immune system. 
Dissecting how the mucosal immune system in the digestive tract fends off non-self attackers, 
like T.suis or T.trichiura, and how is this process interacts with autoimmune disorders. The 
mucosal immune system is made of two distinct parts, the innate immune system and the 
adaptive immune system (NIH, 2003). For the purpose of this paper we will focus on the 
adaptive immune systems T-lymphocytes, also known as T-cells, due to the important part they 
play in the mucosal immune system (McGhee ​et. al​ ., 1992).  
The adaptive immune system is further divided into two sub-categories (humoral and 
cell-mediated). Within the humoral immune system, lymphocytes, specifically B-lymphocytes, 
are the main tracker cells. B-cells mature in the bone marrow, where they undergo rigorous trials 
to insure they are ready to produce the proper antibodies (making sure they will only produce 
antibodies that will tag non-self antigens) (Janeway ​et. al​ ., 2001). Once matured they will travel 
to secondary lymphoid organs and await activation. Each B-cell is highly specific, meaning each 
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will produce a specific antibody for a specific antigen (Janeway ​et. al​ ., 2001). This works for the 
checks and balances part of the humoral immune system, allowing little error for over-reaction to 
other, similar, antigens. When a B-cell is alerted to a specific antigen, it begins to proliferate. 
Soon it will have numerous copies of itself, some being memory B-cells and others being 
effector B-cell (Janeway ​et. al​ ., 2001). The memory B-cell will survive for decades to allow your 
immune system to have a faster and stronger defense towards this specific antigen, preventing 
symptoms from developing during secondary exposure to the pathogen (Janeway ​et. al​ ., 2001). 
On the other side of this system are the effector B-cells. These B-cells will be the ones to poison 
the water supply, so to speak, becoming antibody factories and producing free-flowing 
antibodies that will mark antigens for phagocytosis, complement activation, neutralization or 
precipitation (Janeway ​et. al​ ., 2001). These antibodies will allow macrophages, or other attacker 
cells to identify the pathogenic antigens. 
T-cells fall into four categories, T-helper cells, T-regulatory cells, cytotoxic cells and 
memory cells. T-helper cells play an integral role in both cytoxic (CD-8) T cells and activating B 
lymphocytes for antibody production. T lymphocytes gain immunocompetence in the thymus 
through a process of clonal selection (Janeway ​et. al​ ., 2001). In the immune system, T-helper 
cells act as an activator for the immune system (calling the troops to take up their arms). In a 
similar fashion to a B-cell, T-helper cells are incredibly specific and usually each T-helper cell is 
tuned to one specific antigen. This is again to help the immune system prevent cross-reactivity 
with other (possibly self) antigens. When a T-helper cell is presented its specific antigen by an 
antigen presenting cell (i.e. a B-cell, or dendritic cell, etc.), the T-helper cell will begin to sound 
the alarm (Janeway ​et. al​ ., 2001). This includes proliferation of this specific T-helper cell, and 
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some will become memory T-cells and others will become effector T-helper cells. Memory 
T-helper cells will stick around in the immune system (as was the case for memory B-cells), but 
the effector T-cells will rush into action. Effector T-cells will start to release cytokines, which 
signal other activated immune cells to ramp up production and get ready for battle (Janeway ​et. 
al​ ., 2001). Cytokines are essentially proteins or polypeptides that act as a signaling switch for 
other activated immune cells (i.e. effector B-cells). Earlier in this discussion, it was mentioned 
that when B-cells become activated they proliferate. This activation is made possible and 
monitored by effector T-helper cells (Janeway ​et. al​ ., 2001). This is another way the immune 
system is making sure it actually needs this large response to occur. With all of these ways that 
the immune system has to monitor itself, it seems there is little room for error or self-harm. 
However, in science there are usually exceptions to a rule, and for the immune system, 
autoimmune disorders are the exception. 
Autoimmune diseases are still an elusive topic of research. Many health professionals and 
research scientists are not quite sure what causes certain autoimmune disorders, and have trouble 
coming up with cures or treatments for these diseases. When it comes to the umbrella term of 
inflammatory bowel disease (IBD), it is usually marked by a rise in the T​h​1 and T​h​2 immune 
response (Jackson ​et. al​ ., 2008). T​h​1 and T​h​2 are sub-classifications of the T-helper cells 
discussed earlier in this research, and both give rise to the signature symptom of IBD which is 
inflammation (Jackson ​et. al.,​  2008). When a patient is diagnosed with an autoimmune disease, 
their immune system works in a slightly different way than most. Where a healthy immune 
system would only mark and attack non-self antigens, an immune system with autoimmune 
tendency marks and attacks self-cells. In a simplified explanation, T​h​1 activate cytoxic cells and 
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macrophages to attack self cells and T​h​2 cells activate B lymphocytes to produce antibodies 
against our own healthy cells (Jackson ​et. al.,​  2008). Normally, the body will release a T​h​1 
immune response to an antigen for initial attack, and if it is able to kill and eliminate said antigen 
the body will return to equilibrium. If the antigen is not eliminated by the body’s T​h​1 response, 
then the body will move to a T​h​2 response. A T​h​2 immune response will lead to widespread 
antibody production and a much more powerful response. This cycle between T​h​1 and T​h​2 
immune responses is what causes the cyclic symptoms of IBD(Jackson ​et. al​ ., 2008). The T​h​1 
will start to attack self-cells, causing inflammation and other painful symptoms. If the “antigen” 
is not killed the body cycles into a T​h​2 immune response and starts to produce self-marking 
antibodies, which only proliferate the attack on self-cells (Jackson ​et. al​ ., 2008). It was this 
knowledge of the T​h​1 and T​h​2 immune response that lead researchers to believe that certain 
helminths may be helpful in combating IBD. 
The way helminths, like ​T. suis​  and​ T. trichiura​ , avoid the immune system is by secreting 
suppressor factors as stated earlier. These proteins depress the body’s natural T​h​1 and T​h​2 
immune responses, and therefore decrease the severity of these responses (Jackson ​et. al​ ., 2008). 
Helminthic therapy research is based on the idea that a body with a heightened T​h​1 and T​h​2 
immune responses could be regulated through the use of helminth infection, due to the fact that 
these lymphocyte suppressor factors down regulate the T​h​1/T​h​2 immune response (Jackson ​et. 
al​ ., 2008).  
Part 3A: Article Review 
In the article ​Helminth Regulation of Immunity: A Three-pronged Approach to Treat 
Colitis, ​ Lopes et. al. brought forward three distinct forms of helminthic therapy to treat patients 
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with ulcerative colitis. Lopes ​et. al​ . began their research with a few hypotheses that have driven 
helminthic therapy research. The “red queen hypothesis” states that as the helminth evolves 
better methods to evade its host’s immune system, said host evolves more efficient ways of 
ejecting the parasite from its system (Lopes ​et. al​ ., 2016). Another hypothesis Lopes et. al. 
reference was the “hygiene hypothesis”, stating that a helminth could provide some type of 
protection against concomitant disease. These two hypotheses combined could explain why the 
helminth has been able to coevolve with the human species (Lopes ​et. al​ ., 2016). As the two 
species (human and helminth) kept cycling through evolutionary tactics, the helminth presented 
protection against concomitant diseases. This could be seen as a health benefit to the host, and 
lead to a type of symbiotic lifestyle between host and parasite.  
With these two hypotheses as a basis for research, Lopes ​et.al​ . presented these three 
forms of treatment for colitis: ingestion of viable ova or larvae of a helminth, use of crude 
helminthic extracts, and cellular immunotherapy. The most common type of helminthic therapy 
is through ingestion of viable ova or larvae, and through comparison of animal and human 
models it proves to be successful (Lopes ​et. al​ ., 2016). Lopes et. al. discussed that in human 
models using ​T. suis​  ova or larvae there has been little to no side effects reported. Referencing 
studies that use both open label and placebo methods, Lopes et. al. provided adequate evidence 
of successful studies. However, Lopes ​et. al​ . state that there is a gap between animal (rodent) 
studies and human studies. This gap shows the need for further research of helminthic therapy 
using human patients.  
Lopes et. al. also reviewed the use of helminth-derived extracts in treatment for colitis 
patients. Extracts could include things such as: soluble antigens from adult worms, egg antigens, 
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or simply adult worm extracts (Lopes ​et.al​ ., 2016). The use of these extracts negates the 
concerns of using live parasites for treatment of a patient with ulcerative colitis (Lopes ​et. al​ ., 
2016). Furthermore, these extracts could be used as blueprints for the development of new 
anti-inflammatory drugs (Lopes ​et. al​ ., 2016). By reviewing a study featuring the use of 
Schistosoma mansoni​  (​S. mansoni​ ) egg extracts, Lopes et. al. showcased the success these 
extracts can have. However, in this same study, not all results were positive ​as certain types of 
colitis were not affected by the egg extracts​ (Lopes ​et. al​ ., 2016). This lead the researchers. to 
propose that helminthic therapy research should be conducted with defined patient cohorts. 
Having a defined patient cohort, in this sense, would mean the patients with colitis being studied 
would all have similar types of colitis and similar symptoms in response to the colitis (Lopes ​et. 
al​ ., 2016).  
Thirdly, Lopes, ​et. al​ . proposed the use of cellular immunotherapy as a treatment for 
patients with colitis. Traditionally, cellular immunotherapy is used by transplanting cells into the 
patient in order to combat the disease. Lopes ​et. al​ . proposed transplanting cells from an 
individual infected with helminths to a patient diagnosed with colitis. The viability of this 
treatment has been shown through successful mice models, however there is a feasibility 
limitation when it comes to human patients (Lopes ​et. al​ ., 2016). Even though there is this 
feasibility issue, it is shown that a helminth infection (or the antigens helminths produce) induce 
certain cell phenotypes that could be used for treatment of IBD (Lopes ​et. al​ ., 2016).  
Lopes et. al. concluded that research on treatments for IBD is urgently needed, due to the 
terrible toll colitis can take on patient’s lives. Furthermore, through these three treatment 
methods Lopes ​et. al​ . determined a trend towards a personalized approach in patient care and 
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treatment. Finally, Lopes et. al. concluded that there is definitely a link between host and parasite 
that may be beneficial to the treatment of IBD.  
Helminth Regulation of Immunity: A Three-pronged Approach to Treat Colitis ​ is a useful 
review to examine, because of its overview of three distinct treatment options. Many other 
studies focus their attention on the ingesting of live ova or larvae, and leave out the other options 
of cellular immunotherapy or helminthic extracts. Including these two other methods is 
inventive, and strengthens helminthic therapy research in various ways and broadens the field of 
research for helminthic therapy. Including results from various studies, and comparing those 
results between different treatment options gives a deeper insight into the gap in helminthic 
therapy research. Lopes, ​et. al​ .’s conclusions support helminthic therapy, especially in the sense 
of developing varying forms of treatment options. Some of the drawbacks of this article are 
based in the gap between human and animal trials. Throughout ​Helminth Regulation of 
Immunity: A Three-pronged Approach to Treat Colitis​ , Lopes, ​et. al​ . related the human trials to 
rodent trails that have had more conclusive results. Lopes, ​et. al​ . discussed that the less 
conclusive results in human trials are due to the lack in extensive research in this area. Although 
it seems likely that more research would close this gap in results, there may be other 
explanations as to why the human trials tend to be non-conclusive. One explanation could be the 
way trials are being conducted. Many of the studies using human trials do not have a defined 
patient cohort, which could be skewing their results. Lopes, ​et. al​ . mentioned the great necessity 
for defined patient cohorts in helminthic therapy research. Especially in the realm of cellular 
immunotherapy, the use of a more personalized care plan could drastically change the results of 
some of these studies. Because many autoimmune diseases vary from patient to patient, even 
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when they have the same diagnoses, it makes more sense to vary the treatment method to fit each 
individual.  
Defining a patient cohort for a study of helminthic therapy would involve finding patients 
with similar responses to a specific autoimmune disease. For example, when creating a human 
trial studying colitis patients, the researcher would need to decide on the type of response they 
would be looking into. If they decide to look at an immune response marked by heightened T​h​2 
response, then they would need to test patient candidates for this response before including them 
in the study. This way, researchers can look at several different methods of helminthic therapy, 
and compare the results against one another to determine the best course of treatment. This extra 
setup step would allow researchers to tailor design a treatment method for patients with a 
specific immune response to colitis. Even though this would take more time, effort and money, it 
has the potential to change the lives of those living with IBD. 
Part 3B: Article Review 
Trichuris suis therapy in Crohn’s disease​  is a 24-week open-label study on the safety and 
efficacy of ingesting ​T. suis ​ ova as a treatment for Crohn’s disease. Summers, ​et. al​ . (2004) 
conducted the study on patients with ages ranging from 18 to 72 years old, with a Crohn’s 
disease activity index (CDAI) from 220 to 450. The CDAI is a form of measuring symptoms of 
Crohn’s diseases, where 220 is moderately ill and 450 is severe disease (Summers ​et. al​ ., 2004). 
A score is calculated by taking in various symptoms (i.e. number of liquid stool per day, 
abdominal pain, number of antidiarrheal drugs used) summed over the course of seven days, 
after adjustment by a weighting factor, and relating that score to an average (Summers ​et. al​ ., 
2004) (see table below). 
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Clinical or laboratory variable Weighting 
factor 
Number of liquid or soft ​stools​ each day for seven days x 2 
Abdominal pain​ (graded from 0-3 on severity) each day for seven days x 5 
General well-being, subjectively assessed from 0 (well) to 4 (terrible) each 
day for seven days 
x 7 
Presence of complications​* x 20 
Taking Lomotil or opiates for diarrhea x 30 
Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite) x 10 
Hematocrit​ of <0.47 in men and <0.42 in women x 6 
Percentage deviation from standard weight x 1 
Figure 2: CDAI data table. (Summers ​et. al.,​  2004) 
Along with this age and CDAI range, the patients could be taking immunosuppressant 
drugs as long as it was kept constant. Patients were not allowed in the study if they filled any of 
the following criteria: they were taking immunomodulatory drugs; had previous treatments with 
antibiotic, antifungal, or antiparasitic medications; were diagnosed with diseases other than 
Crohn’s disease; had undergone an ileostomy, colostomy, resection of greater than 50 cm, or had 
obstructive symptoms; or were anticipating the need for surgery.  
The method used to obtain ​T. suis​  ova included using pathogen free pigs, and ensuring 
the ova remained uncontaminated. First the pathogen free pigs were infected with ​T. suis​  ova, 
which were allowed to come to maturation. Once maturation was reached the eggs were 
collected from the colon, and cultured in vitro. The ova were embryonated in a phosphate 
buffered saline solution at 25℃, and kept bacteria free through the use of 0.2% K​2​Cr​2​O​7​ solution 
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and washed with sterile saline solution. Storing the ova at 5℃ also ensured that there was no 
contamination by bacteria or other pathogens (Summers ​et. al​ ., 2004). Through this process of 
obtaining ​T. suis​  ova, Summers et.al. showed that ​T. suis ​ ova can stay viable, when stored 
properly, for up to nine months. This conclusion lends support to the potential for ​T. suis​  ova 
becoming a treatment which could be done by the patient at home with monthly checkups with a 
physician.  
Through this 24-week open-label study, the following procedures were in use. The 
patients were given a dose of 2500 ​T.suis​  ova, suspended in liquid, every three weeks. At the 
time of entry and every six weeks, the following data points were collected: medical history, 
physical examination, pregnancy test, complete blood count, liver profile, stool examination 
checking for ova, pathogens, and ​Clostridium difficile​  toxin. Patients also kept diaries of their 
symptoms, and if a patient was taking immunosuppressant medication the dosage was kept 
constant. Summers ​et.al.​  also used the two-tail Fisher’s exact test to examine characteristics that 
may indicate response or remission.  
Results of this study support the viability and safety of using ​T. suis​  ova as a form of 
treatment for Crohn’s disease. With 75.9% of patients experiencing response (decrease of 
CDAI>100 or CDAI<150) and 65.5% of patients experiencing remission (CDAI<150) by week 
12, this lends hard evidence to helminthic therapy being a viable form of treatment. Then by 
week 24, 79.3% of patients had experienced response and 72.4% of patients experienced 
remission. These results partnered with the mean CDAI decrease being 195.1 by week 12 and 
187.2 by week 24, showing substantial evidence for the viability of helminthic therapy.  
With these results, Summers, et. al. concluded that the use of ​T. suis ​ ova was a safe and 
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effective treatment for Crohn’s disease. Since ​T. suis​  was not a natural parasite for humans, it 
lowered the risk of over-colonization of the patient (Summers ​et. al.,​  2004). This paired with the 
ability to control the source of the ova (pathogen-free pigs), ensured the patient's safety 
throughout the course of treatment. With an 80% response rate and a 73% remission rate, even in 
patients with refractory disease, the outcome of this study clearly shows significant evidence 
towards the viability of helminthic therapy (Summers ​et. al.,​  2004). However, with this study 
being an open-label study, it is impossible to rule out a placebo effect. This means that the results 
from this study justify further research (i.e. a blind clinical study), but cannot have truly 
conclusive results on its own.  
The Summers ​et. al​ . study is important to look at, because of its unique use of the 
Crohn’s disease activity index. Many other studies focus on a change from a cellular level, and 
do not look at patient’s results holistically. By using the CDAI, Summers ​et. al​ . were able to 
show the change helminthic therapy was eliciting in their patient’s lives. Also, this holistic 
approach resulted in a greater change over time than other studies focusing on change in certain 
interleukins or T​h​1/T​h​2 response. While it is valuable to mark the clinical changes from the 
cellular level of a patient, it can be just as valuable to also look at the overall change in 
symptoms a patient is experiencing.  
Trichuris suis therapy in Crohn’s disease ​ did support the viability and safety of 
helminthic therapy, and had substantial evidence behind this conclusion. Summers, ​et. al​ . 
produced viable results that were even better than predicted. Even with the possible placebo 
effect, Summers ​et. al​ . created a new way of viewing helminthic therapy research. With studies 
like these it is easy to see the need for further research, particularly blind studies, but it also 
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showcases the real possibility for helminthic therapy to make a difference in the lives of those 
living with Crohn’s disease. 
Part 3C: Article Review 
Mucosal and systemic immune modulation by Trichuris trichiura in a self-infected 
individual​  is an open label study that consists of one self-infected patient (Dige ​et. al​ ., 2016). 
The purpose of this study was to determine if the helminth ​T. trichiura​  was able to 
immunomodulate a human immune system. Through this study Dige ​et. al​ . could single out the 
immunomodulant aspect of helminthic infect, and rule out the possible interaction of an intestinal 
disease.  
Because this study consisted of a single self-infected patient with no prior intestinal 
disease, the methods used were slightly different than many other helminthic therapy studies. 
The patient was a 38 year-old with untreated psoriasis, but with no prior medical history of 
intestinal disease. Being 1.92 m tall and maintaining a constant body weight of 71 kg, Dige ​et. al​ . 
determined the patient’s daily fecal production to be 250g. This data point is necessary to 
determine the amount of ​T. trichiura ​ ova needed to produce a moderate infection. After factoring 
in the amount of eggs that would actually hatch in the intestine (80%) and the sex ratio (1:1), 
Dige ​et. al.​  decided that a dosage of 600 eggs would produce the infection needed. After nine 
weeks with no eggs in the patient’s feces, the patient voluntarily took an extra three small doses 
of ​T. trichiura ​ eggs. Throughout this infection period, the following data points were collected 
before and after infection: blood and faecal samples (biweekly), biopsies and ileo-colonoscopies 
at four locations (the terminal ileum, the cecum/ascending colon, the transverse colon and the 
sigmoid colon), and monitoring of the patient for signs of diarrhea, anemia, and weight loss. At 
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the end of the study, the helminthic infection was terminated through the use of a mebendazole 
treatment. 
The results Dige ​et. al​ . produced support the immunomodulatory effects of ​T. trichiura 
on a human immune system. This support was shown through a marked rise in T-cell cytokines 
that are directly linked to autoimmune diseases under the umbrella of IBD (i.e. T​h​1/T​h​2). With a 
rise in T-cell cytokines, the patient’s immune system lowered its T​h​1 response and raised its T​h​2 
response. Dige ​et. al​ . conclude that this marked switch in T-cell response shows the ability of ​T. 
trichiura​  to be an immunomodulant for a human immune system. Another interesting result from 
this study was the patient developing ​Campylobacter ​ colitis after the infection with ​T. trichiura​ . 
Dige ​et. al​ . concluded that an infection with helminths may leave the human immune system 
open to infection with other bacteria. Through this finding, Dige ​et. al​ . suggest that future studies 
ensure the patients have no prior infection of ​Campylobacter​ , and that the ova being ingested are 
free of contaminants.  
Mucosal and systemic immune modulation by Trichuris trichiura in a self-infected 
individual​  is an article that brings an entirely new perspective to the study of helminthic therapy. 
Through the use of a patient with no prior intestinal disease, Dige ​et. al​ . were able to produce 
results that negate the coincidental changes in disease activity. Focusing on only the interaction 
between ​T. trichiura​  and the human immune system allowed Dige ​et. al​ . to produce results that 
support the immunomodulatory effects helminths can have on humans. Having conclusive 
evidence of this interaction could further helminthic therapy research, and supports the hygiene 
hypothesis. Through this study Dige ​et. al​ . also found that helminths may leave the human 
immune system vulnerable to co-infection. Even though this result seems negative for the use of 
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helminthic therapy, it was able to provide instruction for future studies. Through this study 
conducted by Dige ​et. al​ ., helminthic therapy research was furthered by the knowledge of the 
immunomodulatory effects of ​T. trichiura ​ has on a human immune system, and given valuable 
instruction to avoid co-infection of ​Campylobacter​ . 
Part 4: Conclusion 
In conclusion, treatment of autoimmune diseases categorized as inflammatory bowel 
disease (IBD) with infection of helminths (​T. suis​ ) is both safe and effective. Though more 
research is needed, evidence of the viability of helminthic therapy is clearly shown in the studies 
discussed in this paper. Researchers Lopes ​et. al​ . in ​Helminth Regulation of Immunity: A 
Three-pronged Approach to Treat Colitis ​ support the use of helminths as a treatment for IBD in 
various forms. These forms include helminth extracts, cellular immunotherapy, and the most 
common method of ingesting live ova or larvae (Lopes ​et. al​ ., 2016). Presenting evidence that 
each of these three forms have produced successful results (patients gaining remission status, or 
positively responding to treatment) in clinical trials, expands helminthic therapy research to 
include these innovative methods.  
In Summers ​et. al​ .’s research, ​Trichuris suis therapy in Crohn’s disease​ , supporting 
evidence was shown through tracking patient progress using the Crohn’s disease activity index 
(CDAI). Using the CDAI to determine the viability of helminthic therapy was a unique way of 
examining results, and provided a holistic approach to Summers ​et. al​ .’s research. Their results 
were positive, with a majority of their patients gaining remission or at least responding positively 
to the treatment (CDAI decreasing by at least 100 points) (Summers ​et. al​ ., 2004). Through this 
supporting evidence, Summers ​et. al​ . were able to provide a new way of examining results of 
17 
helminthic therapy studies.  
Dige ​et. al​ ., authors of ​Mucosal and systemic immune modulation by Trichuris trichiura 
in a self-infected individual​ , also presented concrete results supporting the immunomodulatory 
effects helminths have on a human immune system. By studying a self-infected individual with 
no prior intestinal disease, Dige ​et. al​ . were able to rule out the possibility of coincidental 
changes in disease activity in their results. Having results like these presents concrete evidence 
of the immunomodulatory influence helminths can have on a patient’s immune system (Dige ​et. 
al​ ., 2016). This study solidifies the basis of helminthic therapy research, and warns future 
research of things to avoid.  
After reviewing these three studies, helminthic therapy seems to be a safe and effective 
form of treatment. However, in science, nothing is ever truly proven and research must always be 
followed by more research. For future helminthic therapy research, the following points should 
be taken into consideration. When creating a clinical study, patients should be chosen from a 
defined cohort. A defined patient cohort would limit the influencing variables in a study, 
therefore the results would be more conclusive (Lopes ​et. al​ ., 2016). Future studies should also 
use the CDAI to examine results, and pair this with determining results from a cellular level. 
This would allow studies to view their data comprehensively, thus solidifying their results. 
Finally, future research should ensure a lack of contamination when using live ova or larvae. 
This is important, because helminths can leave the human immune system vulnerable to bacterial 
infection. 
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